​

GridAI Technologies Stock (NASDAQ:GRDX)

RevenueOwnershipFinancialsChart
GridAI Technologies by TradingView

Previous Close

$4.41

52W Range

$1.08 - $6.93

50D Avg

$4.14

200D Avg

$3.51

Market Cap

$14.99M

Avg Vol (3M)

$122.59K

Beta

1.81

Div Yield

-

GRDX Company Profile

GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Oct 11, 2016

Website

GRDX Performance

GRDX Financial Summary

Dec 25Dec 24Dec 23
Revenue$36.25K--
Operating Income$-7.08M$-15.62M$-15.77M
Net Income$-6.55M$-18.06M$-15.79M
EBITDA$-7.08M$-15.57M$-15.74M
Basic EPS$-4.16$-3.88$-46.96
Diluted EPS$-4.16$-5.33$-46.96

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
ASBPAspire Biopharma Holdings, Inc.
PCSAProcessa Pharmaceuticals, Inc.
ATHAAthira Pharma, Inc.
CRISCuris, Inc.
BCTXBriaCell Therapeutics Corp.
LPTXLeap Therapeutics, Inc.
ALLRAllarity Therapeutics, Inc.
CTXRCitius Pharmaceuticals, Inc.
CINGCingulate Inc.
PALIPalisade Bio, Inc.